- Conditions
- Obesity
- Interventions
- Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 35 Years to 60 Years
- Enrollment
- 30 participants
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One, Intensive Medical Combination Therapy for Obesity, Control Condition
- Behavioral · Drug · Other
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Pregnancy, Obesity, Overweight
- Interventions
- No Intervention
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 15 Years to 50 Years · Female only
- Enrollment
- 2,701 participants
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Princeton, New Jersey
- Conditions
- Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
- Interventions
- NRP104
- Drug
- Lead sponsor
- New River Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cardiovascular Kidney Metabolic Syndrome
- Interventions
- Intervention, Active Comparator
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23,280,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio